BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19903094)

  • 1. Optimizing T-cell expansion: have we reached the limit?
    Melenhorst JJ
    Cytotherapy; 2009; 11(7):813-4. PubMed ID: 19903094
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of culture medium on the expansion of T cells for immunotherapy.
    Sato K; Kondo M; Sakuta K; Hosoi A; Noji S; Sugiura M; Yoshida Y; Kakimi K
    Cytotherapy; 2009; 11(7):936-46. PubMed ID: 19903105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive T-cell immunotherapy of cancer.
    Li Q; Chang AE
    Cytokines Cell Mol Ther; 1999 Jun; 5(2):105-17. PubMed ID: 10515683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor reactive T cells get a boost.
    Pardoll DM
    Nat Biotechnol; 2002 Dec; 20(12):1207-8. PubMed ID: 12454671
    [No Abstract]   [Full Text] [Related]  

  • 5. Antigen choice in adoptive T-cell therapy of cancer.
    Offringa R
    Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
    Peinert S; Kershaw MH; Prince HM
    Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
    [No Abstract]   [Full Text] [Related]  

  • 7. Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer.
    Hombach AA; Abken H
    Immunotherapy; 2013 Jul; 5(7):677-81. PubMed ID: 23829616
    [No Abstract]   [Full Text] [Related]  

  • 8. Current developments of immunotherapy in the clinic.
    Antonia S; Mulé JJ; Weber JS
    Curr Opin Immunol; 2004 Apr; 16(2):130-6. PubMed ID: 15023403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical development of T cell receptor gene therapy.
    Bendle GM; Haanen JB; Schumacher TN
    Curr Opin Immunol; 2009 Apr; 21(2):209-14. PubMed ID: 19321326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-specific T cells combine proliferation and antitumor activity.
    Kershaw MH; Westwood JA; Hwu P
    Nat Biotechnol; 2002 Dec; 20(12):1221-7. PubMed ID: 12415288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the stroma by T cells to limit tumor growth.
    Zhang B
    Cancer Res; 2008 Dec; 68(23):9570-3. PubMed ID: 19047130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
    Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
    J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic redirection of T cells for cancer therapy.
    Westwood JA; Kershaw MH
    J Leukoc Biol; 2010 May; 87(5):791-803. PubMed ID: 20179152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
    Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
    Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The promise of T-lymphocyte immunotherapy for the treatment of malignant disease.
    Thomas AK; June CH
    Cancer J; 2001; 7 Suppl 2():S67-75. PubMed ID: 11777267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antitumor cellular immunotherapy: the breakthrough of dendritic cells].
    Angevin E; André F; Zitvogel L
    Bull Cancer; 2000 Jan; 87(1):107-15. PubMed ID: 10673639
    [No Abstract]   [Full Text] [Related]  

  • 17. Quality and quantity: new strategies to improve immunotherapy of cancer.
    Krueger C; Schneck JP; Oelke M
    Trends Mol Med; 2004 May; 10(5):205-8. PubMed ID: 15121045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations on clinical use of T cell immunotherapy for cancer.
    Plautz GE; Cohen PA; Shu S
    Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
    Cohen PA; Peng L; Kjaergaard J; Plautz GE; Finke JH; Koski GK; Czerniecki BJ; Shu S
    Crit Rev Immunol; 2001; 21(1-3):215-48. PubMed ID: 11642606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
    Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
    Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.